Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
about
Many multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesImpact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialEvidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapieImmunomodulatory drugs in multiple myeloma.Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myelomaInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideImproving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.Challenges in multiple myeloma diagnosis and treatment.Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesLenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.Current multiple myeloma treatment strategies with novel agents: a European perspectiveLenalidomide in multiple myeloma: current role and future directions.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.Treatment of newly diagnosed myeloma in patients not eligible for transplantation.Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Guidelines for the diagnosis and management of multiple myeloma 2011.Plasma cell myeloma and related neoplasms.Genomic stratification of multiple myeloma treated with novel agents.Update on risk stratification and treatment of newly diagnosed multiple myeloma.Lenalidomide in multiple myeloma: Current status and future potential.Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.Current and potential epigenetic targets in multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
P2860
Q26852892-1D6D1C9B-EB45-40A2-8447-4B7D96590D1FQ27026205-C4203ACB-9C40-4BC5-A9F4-68E21AE0C70CQ30424188-78217A25-BE9B-4A32-86DA-B324D592FD4FQ30433139-58783358-79C7-4234-9895-10F2ABD053D4Q33884167-6B5768A0-E3D5-454B-B94A-41460EB79408Q34325722-4BA98EED-0EC5-417E-AB93-84D77B656F88Q34541542-10DD1DB8-F02A-4440-9202-101291424D79Q35265979-3C0D9B45-3B49-4E52-A0AB-E97877257779Q35713446-7EA67C0D-9017-4C1A-8DD3-F63C05762689Q35802414-DC0AC59D-6582-47B8-8436-34DBBA6A9C0AQ35868171-C01E9E28-3D32-4989-91F8-55C5D71D3447Q36526999-0CFC63A0-205F-4762-9EA3-3BB33C2FCC3AQ36544516-ADBB9837-40F9-4EA1-8845-4E74E8CB48FBQ36595290-4A7FA991-5CBF-4BDE-9728-F0C3B9315B6BQ36852225-FD182747-48DA-4353-A4AF-488B0ED7AAD9Q36925154-B1219FA5-48F6-4AA2-8549-19B40A161255Q37037265-5214EAE2-9B77-48D9-AFF5-876944DCC02FQ37397995-D9B89EEF-227C-4948-9069-AEADCFC3F513Q37454445-21F14EBA-743C-4856-88E8-92D068212E2EQ37515416-42F592DD-6982-4B0B-A4C3-CA8852C020C8Q37677935-90EE4974-EAB7-4E1C-859A-A092716BB06EQ37704401-7EB69787-026A-440C-A23B-9E7DB676F5C2Q37800884-EEBD7642-8811-4D7B-8AF9-E431A5816C2BQ37835572-66B8CE86-BCE2-457F-9169-A9005F0C71D0Q37835695-1C0FC25D-6030-4996-A203-703DABF3174BQ37846567-22EC41A0-7C19-4F17-A700-7FCB48935902Q37851855-8ECF4D3F-E86F-49CB-AF50-16D64AD59125Q37851944-2288B583-3FEF-43BA-8DDC-05F894823DB0Q37875193-8A20076B-A0C6-4CAF-9062-765664DD0321Q37901231-BFA48B1B-3A8A-4E10-989B-A6D02D81F14FQ37913346-AB73A1F1-31A8-4C5F-9BE3-7A6D19DEDD24Q37946701-31C0ABF8-1EDD-40F6-9DF2-AE2E8E12E4C4Q38013995-2FF462A9-BF04-41CE-99D3-DCAA5EBB857DQ38031989-A1D7C327-4009-427D-8B97-5B47FB5B8A79Q38037600-BE080CD7-768F-4610-8A69-B9883E76E09EQ38108391-3AF164EA-CFD9-4C5A-98EA-92FBA74B9827Q38155425-6F803A08-135D-46D0-B482-FD822315C25FQ38210475-DD51950C-3225-447F-87A4-405A3025BB05Q38413040-B2B162B5-5C77-4156-A5FE-D38F34F6A275Q38462720-F7786078-9103-4EF6-9856-9A55C15218C4
P2860
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of risk stratification ...... lenalidomide and dexamethasone
@en
Impact of risk stratification ...... enalidomide and dexamethasone.
@nl
type
label
Impact of risk stratification ...... lenalidomide and dexamethasone
@en
Impact of risk stratification ...... enalidomide and dexamethasone.
@nl
prefLabel
Impact of risk stratification ...... lenalidomide and dexamethasone
@en
Impact of risk stratification ...... enalidomide and dexamethasone.
@nl
P2093
P2860
P50
P1433
P1476
Impact of risk stratification ...... lenalidomide and dexamethasone
@en
P2093
A Keith Stewart
Craig B Reeder
Francis Buadi
John A Lust
Joseph R Mikhael
P Leif Bergsagel
Philip R Greipp
Prashant Kapoor
Rafael Fonseca
Robert J Dalton
P2860
P304
P356
10.1182/BLOOD-2009-01-202010
P407
P50
P577
2009-03-26T00:00:00Z